# Orelabrutinib Plus Rituximab Followed by Maintenance With Orelabrutinib for Relapsed and Refractory Follicular Lymphoma(RR FL)

> **NCT04989621** · PHASE2 · RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 32 (estimated)

## Conditions studied

- Follicular Lymphoma
- Relapsed and Refractory Follicular Lymphoma

## Interventions

- **DRUG:** Orelabrutinib and Rituximab
- **DRUG:** Orelabrutinib

## Key facts

- **NCT ID:** NCT04989621
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-08-01
- **Primary completion:** 2026-08
- **Final completion:** 2028-08
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2026-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04989621

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04989621, "Orelabrutinib Plus Rituximab Followed by Maintenance With Orelabrutinib for Relapsed and Refractory Follicular Lymphoma(RR FL)". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT04989621. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*